The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
A Comprehensive Map of FDA-Approved Pharmaceutical Products
Open accessAbstract
With the increasing research and development (R&D) difficulty of new molecular entities (NMEs), novel drug delivery systems (DDSs) are attracting widespread attention. This review investigated the current distribution of Food and Drug Administration (FDA)-approved pharmaceutical products and evaluated the technical barrier for the entry of generic drugs and highlighted the success and failure of advanced drug delivery systems. According to the ratio of generic to new drugs and the four-quadrant classification scheme for evaluating the commercialization potential of DDSs, the results showed that the traditional dosage forms (e.g., conventional tablets, capsules and injections) with a lower technology barrier were easier to reproduce, while advanced drug delivery systems (e.g., inhalations and nanomedicines) with highly technical barriers had less competition and greater market potential. Our study provides a comprehensive insight into FDA-approved products and deep analysis of the technical barriers for advanced drug delivery systems. In the future, the R&D of new molecular entities may combine advanced delivery technologies to make drug candidates into more therapeutically effective formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
WITHDRAWN—a resource for withdrawn and discontinued drugs
Siramshetty, V. B., Nickel, J., Omieczynski, C., Gohlke, B.-O., Drwal, M. N., & Preissner, R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1192 · Cited by 286
RetractedDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Malam, Y., Loizidou, M., & Seifalian, A. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.004 · Cited by 1,318
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Biodegradable microspheres for protein delivery
Sinha, V. R., & Trehan, A. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00194-9 · Cited by 814
Formulation strategy and use of excipients in pulmonary drug delivery
Pilcer, G., & Amighi, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.017 · Cited by 791
Controlled drug delivery systems: Past forward and future back
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 720
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695
Mechanisms of macromolecule absorption by the lungs
Patton, J. S. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00113-l · Cited by 641
Transdermal patches: history, development and pharmacology
Pastore, M. N., Kalia, Y. N., Horstmann, M., & Roberts, M. S. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13059 · Cited by 586
An overview of clinical and commercial impact of drug delivery systems
Anselmo, A. C., & Mitragotri, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.053 · Cited by 520
Silverman, J. A., & Deitcher, S. R. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2042-4 · Cited by 474
The lung as a route for systemic delivery of therapeutic proteins and peptides
Uchenna Agu, R., Ikechukwu Ugwoke, M., Armand, M., Kinget, R., & Verbeke, N. (2001) · Respiratory Research · doi:10.1186/rr58 · Cited by 411
The Structure Of Normal Skin And The Morphology Of Atopic Eczema
Mihm, M. C., Soter, N. A., Dvorak, H. F., & Austen, K. F. (1976) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12514346 · Cited by 382
Controlled Drug Delivery: Historical perspective for the next generation
Yun, Y. H., Lee, B. K., & Park, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.005 · Cited by 378
AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
Adler-Moore, J., & Proffitt, R. T. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.21 · Cited by 339
Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing
Goyanes, A., Chang, H., Sedough, D., Hatton, G. B., Wang, J., Buanz, A., Gaisford, S., & Basit, A. W. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.10.039 · Cited by 330
Trends in clinical success rates
Smietana, K., Siatkowski, M., & Møller, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.85 · Cited by 277 · cited 1×
“However, the success rate of NMEs in clinical trials is merely about 10% [2,3].”
BackgroundLiposomal bupivacaine: a review of a new bupivacaine formulation
Cummings, III, & Chahar (2012) · Journal of Pain Research · doi:10.2147/jpr.s27894 · Cited by 272
Fundamentals of pulmonary drug delivery
GRONEBERG, D. A., WITT, C., WAGNER, U., CHUNG, K. F., & FISCHER, A. (2003) · Respiratory Medicine · doi:10.1053/rmed.2002.1457 · Cited by 270
Principles of Metered-Dose Inhaler Design
Newman, S. P. (2005) · Respiratory Care · doi:10.4187/respcare.05501177 · Cited by 244
Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN)
Schwarz, C., & Mehnert, W. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00222-6 · Cited by 234
DIMINISHED BACTERIAL DEFENCES WITH INTRALIPID
Fischer, G., Wilson, S., Hunter, K., & Mease, A. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90171-3 · Cited by 233
Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice
(2010) · Wiley eBooks · doi:10.1002/9780470640487 · Cited by 214
Onivyde for the therapy of multiple solid tumors
Zhang, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105587 · Cited by 187
Sandostatin LAR in Acromegalic Patients: Long Term Treatment
Fløgstad, A. K., Halse, J., Bakke, S. J., Lancranjan, I., Marbach, P., Bruns, C., & Jervell, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3572 · Cited by 176
Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
Zheng, P.-P., Kros, J. M., & Li, J. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.02.012 · Cited by 171
Liposomal bupivacaine: a review of a new bupivacaine formulation
Chahar, P., & Cummings, III (2012) · Dove Medical Press (Taylor and Francis Group) · Cited by 156
Jacob, H. S., & Lux, S. E. (1968) · Blood · doi:10.1182/blood.v32.4.549.549 · Cited by 145
Multi-layered hydrophilic matrices as constant release devices (GeomatrixTM Systems)
Conte, U., Maggi, L., Colombo, P., & Manna, A. L. (1993) · Journal of Controlled Release · doi:10.1016/0168-3659(93)90207-l · Cited by 139
Mullard, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.4 · Cited by 137
Medical Aerosol Inhalers: Past, Present, and Future
Clark, A. R. (1995) · Aerosol Science and Technology · doi:10.1080/02786829408959755 · Cited by 135
Phuphanich, S., Maria, B., Braeckman, R., & Chamberlain, M. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9218-x · Cited by 122
History of Aerosol Therapy: Liquid Nebulization to MDIs to DPIs
ANDERSON, P. J. (2005) · Respiratory Care · doi:10.4187/respcare.05501139 · Cited by 120
Predicting oral disintegrating tablet formulations by neural network techniques
Han, R., Yang, Y., Li, X., & Ouyang, D. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.01.003 · Cited by 95
Self-citationDrug delivery of the future: Chasing the invisible gorilla
Park, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.048 · Cited by 90
Garg, S. K., Carmain, J. A., Braddy, K. C., Anderson, J., Vignati, L., Jennings, M. K., & Chase, H. P. (1996) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199601)13:1<47::aid-dia999>3.0.co;2-m · Cited by 86
Naltrexone: A review of existing sustained drug delivery systems and emerging nano-based systems
Goonoo, N., Bhaw‐Luximon, A., Ujoodha, R., Jhugroo, A., Hulse, G. K., & Jhurry, D. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.046 · Cited by 75
Formulation techniques for high dose dry powders
Brunaugh, A. D., & Smyth, H. D. C. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.05.036 · Cited by 60
Digital medicines: clinical review on the safety of tablets with sensors
Plowman, R. S., Peters-Strickland, T. S., & Savage, G. M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1508447 · Cited by 57
Evolution of Oral Controlled Release Dosage Forms
Lee, P. I., & Li, J. (2010) · doi:10.1002/9780470640487.ch2 · Cited by 56
Bobo, W. V., & Shelton, R. C. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.143 · Cited by 53
Impact of the Pharmaceutical Sciences on Health Care: A Reflection over the Past 50 Years
Rowland, M., Noe, C. R., Smith, D. A., Tucker, G. T., Crommelin, D. J. A., Peck, C. C., Rocci, M. L., Besançon, L., & Shah, V. P. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23295 · Cited by 49
Inhaled Human Insulin (Exubera??): A Review of its Use in Adult Patients with Diabetes Mellitus
Dunn, C. J., & Curran, M. P. (2006) · Drugs · doi:10.2165/00003495-200666070-00019 · Cited by 33
Technosphere Insulin (Afrezza): A New, Inhaled Prandial Insulin
Nuffer, W. A., Trujillo, J. M., & Ellis, S. L. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014554648 · Cited by 31
Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent.
Daghistani, N., & Rey, J. A. (2016) · PubMed Central · Cited by 25
Big data analysis of global advances in pharmaceutics and drug delivery 1980–2014
Zhang, W., Zhao, Q., Deng, J., Yuanjia, H., Wang, Y., & Ouyang, D. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.012 · Cited by 24
Self-citationSolvent−Solute Interactions in Hydrofluoroalkane Propellants
Peguin, R. P. S., & da Rocha, S. R. P. (2008) · The Journal of Physical Chemistry B · doi:10.1021/jp710717s · Cited by 23
Cited by
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Clinical translation of nanomedicines: Challenges, opportunities, and keys
Younis, M. A., Tawfeek, H. M., Abdellatif, A. A. H., Abdel-Aleem, J. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114083 · Cited by 462
Zero-order drug delivery: State of the art and future prospects
Laracuente, M.-L., Yu, M. H., & McHugh, K. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.020 · Cited by 384
Metadata
- Authors
- Zhong, H., Chan, G., Hu, Y., Hu, H., & Ouyang, D.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2018-12-06
- Volume
- 10
- Issue
- 4
- Pages
- 263
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W2902095884
- Cited by
- 288
- References
- 49
- FWCI
- 40.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.